Aurora Cannabis, one of the largest Canadian marijuana producers, is going public on the New York Stock Exchange.

Shares will start trading on Tuesday morning.

Aurora is joining a select list of Canadian cannabis producers, including Tilray and Cronos, that are able to list on US-based exchanges.

Aurora Cannabis, one of the largest Canadian marijuana producers, is going public on the New York Stock Exchange. When Aurora’s shares start trading on Tuesday morning, the company will join a select list of cannabis producers that are listing on US-based exchanges.

While US-based exchanges were initially reluctant to list Canadian marijuana producers, companies including Tilray (which conducted an initial public offering on the Nasdaq in July), Cronos Group, and Canopy Growth all now list on US exchanges.

“We believe that the legalization in Canada offers a road map to invest in the companies that will form the basis of the legal cannabis industry in the coming years,” Jon Trauben, a managing partner at the cannabis-focused Altitude Investment Management, previously told Business Insider.

To get listed on a US exchange like the NYSE, cannabis producers have to prove they are not violating any federal laws by shipping cannabis into the US, except under specific circumstances.

Read more: Some of the hottest companies in the booming cannabis sector are going on hiring sprees as Canada’s legal marijuana market opens

Aurora already trades on the Toronto Stock Exchange under the ticker ACB. The Edmonton-based cultivator grows cannabis for both the adult-use and medicinal markets.

Lees ook op Business Insider RIVM-baas Van Dissel: coronagolf komt door ons eigen gedrag – werkgevers doen oproep om tweede lockdown te voorkomen

Aurora’s market capitalization has gained over 100% since the middle of August. On August 15, the beverage giant Constellation Brands announced it was upping its stake to $4 billion in an Aurora rival, Canopy Growth.

Last week, marijuana became legal in Canada. Legalization, however, didn’t have the impact most investors had hoped for. Stocks got slammed as traders dumped shares. Aurora sank over 12% on Monday ahead of Tuesday’s NYSE listing.

Foto: An employee in a laboratory at the headquarters of the Austrian Agency for Health and Food Safety in Vienna on March 15.sourceREUTERS/Leonhard Foeger

Coca-Cola is looking into producing CBD-infused beverages with Aurora

Coca-Cola is reportedly eyeing a deal with Aurora to produce beverages infused with cannabidiol, a nonpsychoactive ingredient in marijuana known as CBD, for the Canadian market.

Neither company confirmed the rumors when contacted by Business Insider.

Analysts and investors, however, said they weren’t surprised to hear the rumors and told Business Insider that it would be a smart move on Coca-Cola’s part.

“We are seeing high-profile companies, in addition to institutional investors, waking up to opportunities in the space,” Ben Kovler, the CEO of the publicly traded Green Thumb Industries, said.

Challenges do remain for corporations in the cannabis industry. For one, banks are unwilling to lend money to companies that deal with marijuana, as the plant is considered an illegal, Schedule I drug by the US federal government.

“The challenge remains that until the U.S. government de-schedules cannabis, companies like Coca-Cola will be hamstrung to produce innovative cannabis products with American operators,” Kevin Murphy, the CEO of Acreage Holdings, which counts former politicians such as John Boehner on its board, said.

Aurora is also hiring like crazy as Canada’s legal marijuana market opens. The company has a whopping 11 pages of job openings on its website. These positions are based across Canada and range from high-level executive positions to laboratory research positions and industrial cleaners.

For some cannabis companies, a listing on a US-based exchange is a golden ticket – but it won’t get easier for companies to list as long as the product remains illegal at the federal level.

“Canada has this big finger that is wagging, that is pointing down to us in the US saying, ‘How come you can’t get your stuff together?'” Adam Bierman, the CEO of the cannabis dispensary chain MedMen, told Business Insider.

Read more of Business Insider’s cannabis industry coverage: